Pleiotropic effects of angiotensin-converting enzyme inhibitors and the future of cachexia therapy

Journal of the American Geriatrics Society

Volumn 53, Issue 11, 2005, Pages 2030-2031

  Von Haehling, Stephan ^a   Sandek, Anja ^b   Anker, Stefan D ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; PLACEBO; SPIRONOLACTONE;

CACHEXIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; EDITORIAL; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; PLEIOTROPY; WEIGHT REDUCTION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CACHEXIA; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 29244448711     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.53571.x     Document Type: Editorial

References (15)

1. Stewart S, MacIntyre K, Hole DJ et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315-322.
2. Anker SD, Negassa A, Coats AJ et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin- converting-enzyme inhibitors: An observational study. Lancet 2003;361:1077-1083.
3. Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-1053.
4. Anker SD, Coats AJ. Cardiac cachexia. A syndrome with impaired survival and immune and neuroendocrine activation. Chest 1999;115:836-847.
5. Higashi Y, Sasaki S, Nakagawa K et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: A multicenter study. J Am Coll Cardiol 2000;35:284-291.
6. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: A specific target for hypertension management. Am J Hypertens 1999;12:205S-213S.
7. O'Keefe JH, Wetzel M, Moe RR et al. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol 2001;37:1-8.
8. Kawano H, Do YS, Kawano Y et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000;101:1130-1137.
9. Franz IW, Tonnesmann U, Muller JF. Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. Am J Hypertens 1998;11:631-639.
10. Mosterd A, D'Agostino RB, Silbershatz H et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999;340:1221-1227.
11. Schellenbaum GD, Smith NL, Heckbert SR et al. Weight loss, muscle strength and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J Am Geriatr Soc 2005;53:1996-2000.
12. Ark Therapeutics. Available at www.arktherapeutics.com Accessed June 16, 2005.
13. Tanabe's Major Products. Available at www.tanabe.co.jp/english/drugops/ products.html Accessed June 16, 2005.
14. Ark Therapeutics Group plc: Ark Strengthens International Patent Position on Leading Products. Available at http//virtualtrials.com/news3.cfm?item=3122 Accessed June 16, 2005.
15. von Haehling S, Genth-Zotz S, Anker SD et al. Cachexia: A therapeutic approach beyond cytokine antagonism. Int J Cardiol 2002;85:173-183.